Drug intelligence / Profile preview

EX042-002-05

Development stage: Preclinical
Lead developer: Excelsior Biopharma
Modality: Small Molecules
Administration: Oral

Overview

EX042-002-05 is a preclinical-stage small molecule inhibitor of the transforming growth factor beta (TGF-β) receptor, developed by Excelsior. It is currently in the lead generation phase for the treatment of various fibrotic conditions, including pulmonary fibrosis, systemic sclerosis, liver cirrhosis, cardiovascular disease, and progressive kidney disease. The drug's mechanism involves the regulation or inhibition of TGF-β signaling, which is a central driver in the development and progression of tissue fibrosis across multiple organ systems.

Targets

Transforming growth factor-beta signaling axis

Beyond the preview

Go deeper on EX042-002-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX042-002-05.

Explore the full profile